TY - JOUR
T1 - Comparison of the effects of CORM-2, CORM-3 and CORM-A1 on coagulation in human plasma
AU - Nielsen, Vance G.
AU - Garza, Joshua I.
N1 - Publisher Copyright:
© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins.
PY - 2014
Y1 - 2014
N2 - Carbon monoxide derived from the catalytic action of heme oxygenase-1 or carbon monoxide-releasing molecules (CORMs) has been found to potentially be an anticoagulant or procoagulant agent. Of interest, two water-soluble CORMs, CORM-3 and CORM-A1, recently became commercially available. Thus, the purpose of the present study was to assess and compare the effects of the previously well studied CORM-2 to the effects of CORM-3 and CORM-A1oncoagulationincitratedhuman plasma with thrombelastography. Plasma exposed to CORMs was incubated at 37-C for at least one carbon monoxide release half-time, and then tissue factor-activated coagulation was commenced with calcium addition. CORM-2 and CORM-3 enhanced the velocity of clot formation and thrombus strength in a similar manner, whereas CORM-A1 did not affect coagulation. However, CORM-A1 did diminish tissuetype plasminogen activator initiated fibrinolysis. The similarity in effect on coagulation by CORM-2 and CORM-3 was likely secondary to the relatively inert effect of their ruthenium-containing carrier molecule, whereas the boroncontaining CORM-A1 may have had no effect secondary to boron binding to fibrinogen, preventing carbon monoxidemediated changes in fibrinogen protein structure via attached heme group(s). Future investigations with CORMs should have special attention to confounding effects of the carrier molecule.
AB - Carbon monoxide derived from the catalytic action of heme oxygenase-1 or carbon monoxide-releasing molecules (CORMs) has been found to potentially be an anticoagulant or procoagulant agent. Of interest, two water-soluble CORMs, CORM-3 and CORM-A1, recently became commercially available. Thus, the purpose of the present study was to assess and compare the effects of the previously well studied CORM-2 to the effects of CORM-3 and CORM-A1oncoagulationincitratedhuman plasma with thrombelastography. Plasma exposed to CORMs was incubated at 37-C for at least one carbon monoxide release half-time, and then tissue factor-activated coagulation was commenced with calcium addition. CORM-2 and CORM-3 enhanced the velocity of clot formation and thrombus strength in a similar manner, whereas CORM-A1 did not affect coagulation. However, CORM-A1 did diminish tissuetype plasminogen activator initiated fibrinolysis. The similarity in effect on coagulation by CORM-2 and CORM-3 was likely secondary to the relatively inert effect of their ruthenium-containing carrier molecule, whereas the boroncontaining CORM-A1 may have had no effect secondary to boron binding to fibrinogen, preventing carbon monoxidemediated changes in fibrinogen protein structure via attached heme group(s). Future investigations with CORMs should have special attention to confounding effects of the carrier molecule.
KW - Carbon monoxide releasing molecules
KW - Thrombelastography
UR - http://www.scopus.com/inward/record.url?scp=84927699179&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927699179&partnerID=8YFLogxK
U2 - 10.1097/MBC.0000000000000146
DO - 10.1097/MBC.0000000000000146
M3 - Article
C2 - 25058038
AN - SCOPUS:84927699179
SN - 0957-5235
VL - 25
SP - 801
EP - 805
JO - Blood Coagulation and Fibrinolysis
JF - Blood Coagulation and Fibrinolysis
IS - 8
ER -